{"ModuleTitle": "Company Description", "CompanyName": "Sarepta Therapeutics, Inc.", "Symbol": "SRPT", "Address": "215 FIRST STREET SUITE 415, CAMBRIDGE, Massachusetts, 02142, United States of America", "Phone": "617-274-4000", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a commercial-stage biopharmaceutical company focused on helping patients\r\nthrough the discovery and development of unique RNA-targeted therapeutics, gene\r\ntherapy and other genetic therapeutic modalities for the treatment of rare\r\ndiseases. Applying our proprietary, highly-differentiated and innovative\r\ntechnologies, and through collaborations with our strategic partners, we are\r\ndeveloping potential therapeutic candidates for a broad range of diseases and\r\ndisorders, including Duchenne muscular dystrophy (\"DMD\"), Limb-girdle muscular\r\ndystrophies (\"LGMDs\"), Mucopolysaccharidosis type IIIA (\"MPS IIIA\") and other\r\nneuromuscular and central nervous system (\"CNS\") related disorders. \r\n\r\nOur first commercial product, EXONDYS 51 (eteplirsen) Injection (\"EXONDYS 51\"),\r\nwas granted accelerated approval by the U.S. Food and Drug Administration\r\n(\"FDA\") on September 19, 2016.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f26%2f0001564590-20-006769.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Douglas S. Ingram", "title": "President, Chief Executive Officer & Director"}, {"name": "Gilmore O'Neill", "title": "Chief Medical Officer & Senior Vice President"}, {"name": "Sandesh Mahatme", "title": "Chief Financial & Business Officer, Executive VP"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}